DENVER – The use of adjuvant chemotherapy in early-stage non-small cell lung cancer (NSCLC) patients improves overall survival (OS) and 5-year OS in patients with tumor sizes ranging from 3.1 – 7 cm.

DENVER – The International Association for the Study of Lung Cancer (IASLC) praises the U.S. Food and Drug Administration’s (FDA) decision to approve the first blood test to detect an oncogenic driver mutation in non-small cell lung cancer (NSCLC). This marks a significant step forward in lung cancer treatment. The cobas EGFR Mutation Test v2 detects epidermal growth factor receptor (EGFR) gene mutations and the FDA approved. It is a blood-based companion diagnostic for the EGFR tyrosine kinase inhibitor erlotinib (Tarceva).

June 2016 Newsletter

IASLC‘s Asia Pacific Lung Cancer Conference (APLCC) was held in mid-May in beautiful Chiang Mai, Thailand.

DENVER – The International Association for the Study of Lung Cancer (IASLC) joins the World Health Organization (WHO) in supporting World No Tobacco Day, held May 31, 2016 and reinforces the push for “plain packaging” on cigarette containers. Plain packaging aims to reduce the attractiveness and appeal of tobacco products, to increase the noticeability and effectiveness of mandated health warnings, and to educate consumers about the dangers of smoking.

CHIANG MAI, THAILAND – The biennial Asia Pacific Lung Cancer Conference (APLCC 2016) was successfully organized in Chiang Mai, Thailand (13-15 May 2016) by the International Association for the Study of Lung Cancer (IASLC), Thai Society of Clinical Oncology (TSCO), Chiang Mai Lung Cancer Group and Faculty of Medicine, Chiang Mai University (CMU). More than 870 participants from 26 countries with a wide range of expertise spanning prevention, treatment, research, and care and support fields actively participated in this regional meeting.

DENVER – The International Association for the Study of Lung Cancer (IASLC) created the 2016 consensus statement on optimizing management of epidermal growth factor receptor (EGFR) mutation positive (M+) non-small cell lung cancer (NSCLC) patients, published in the Journal of Thoracic Oncology (JTO), to discuss key pathologic, diagnostic, and therapeutic considerations. The statement also makes recommendations for clinical guidance and research priorities, such as optimal choice of EGFR tyrosine kinase inhibitors (TKIs), management of brain metastasis, role of re-biopsies, and use of circulating free DNA (cfDNA) for molecular studies.